down arrow

Atea Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US04683R1068
USD
3.09
0.09 (3.0%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Phibro Animal Health Corp.
Soleno Therapeutics, Inc.
Arcutis Biotherapeutics, Inc.
Ovid Therapeutics, Inc.
MacroGenics, Inc.
EyePoint Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc.
Erasca, Inc.
Fulcrum Therapeutics, Inc.
Atea Pharmaceuticals, Inc.
Third Harmonic Bio, Inc.
Why is Atea Pharmaceuticals, Inc. ?
Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report
Verdict Report
Icon
No Data Found
Is Atea Pharmaceuticals, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Atea Pharmaceuticals, Inc.
-11.21%
-0.45
44.98%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-237.63%
EBIT to Interest (avg)
-79.08
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0.29
Tax Ratio
0.65%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
75.98%
ROCE (avg)
0
ROE (avg)
2.23%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.66
EV to EBIT
0.94
EV to EBITDA
0.94
EV to Capital Employed
11.26
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1197.73%
ROE (Latest)
-33.93%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company
NET PROFIT(HY)

Higher at USD -71.43 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

0What is not working for the Company
Icon
NO KEY NEGATIVE TRIGGERS
Here's what is working for Atea Pharmaceuticals, Inc.
Net Profit
Higher at USD -71.43 MM
than preceding 12 month period ended Jun 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."